Vor Biopharma Inc. (VOR) company profile
Close on Nov 13, 2026Market cap $1.19BP/E –Yield –
About Vor Biopharma
Biological Products, (No Diagnostic Substances), SIC 2836
Vor Biopharma Inc. is a clinical-stage biopharmaceutical company that develops therapies for autoimmune diseases. Its primary product candidate is telitacicept, a novel fusion protein designed to inhibit B cell lymphocyte stimulator and a proliferation-inducing ligand. By targeting these signaling molecules, the therapy reduces autoimmune responses driven by B cells. The company develops treatments for chronic conditions such as generalized myasthenia gravis and Sjögren’s disease, aiming to serve patients suffering from these neuromuscular and autoimmune illnesses.
Vor Biopharma conducts clinical development programs internationally, maintaining clinical trial sites across the United States, Europe, South America, and Asia. The company holds exclusive rights to develop and commercialize telitacicept in territories outside of Greater China. Its principal executive offices are located in Boston, Massachusetts.
Summary of the business section of Vor Biopharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Vor Biopharma Inc.
- Headquarters
- Boston, MA
- Address
- 500 Boylston Street, Suite 1350 02116
- Phone
- (617) 655-6580
- Website
- vorbio.com
- Employees
- 76, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- VOR
- Exchange
- Nasdaq
- IPO date
- Feb 8, 2021
- Shares outstanding
- 61M, Oct 26, 2026
- Public float
- $76.10M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-20 reverse, Sep 19, 2025
- SEC CIK
- 1817229
- CUSIP
- 929033108
- ISIN
- US9290331084
- FIGI
- BBG00NBJRDT6
- Share class FIGI
- BBG00NBJRDV3
- EIN
- 81-1591163
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jean-Paul Kress | CEO and Chairman, Director | – |
| Robert Ang | PRESIDENT AND CEO, Director | 911,318 |
| Jeremy Brett Sokolove | Chief Medical Officer | 25,983 |
| Sandesh Mahatme | CFO | 0 |
| Qing Che Zuraw | Chief Development Officer | 937,080 |
| Tirtha Chakraborty | Chief Sci Off & Head Tech Ops | 217,416 |
| Han Wook Choi | Chief Financial Officer | 51,280 |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | 126,625 |
| David Zaccardelli | Director | – |
| Alexander Cumbo | Director | – |
| Fouad Namouni | Director | – |
| Michel Detheux | Director | – |
| Wouter Joustra | Director | – |
| Andrew David Levin | Director | – |
| Erez Kalir | Director | – |
| Daniella Beckman | Director | – |
| RA Capital Nexus Fund, L.P. | Director | 1,401,226 |
| Sarah Burgess Reed | Director | – |
| Matthew R. Patterson | Director | 41,196 |
| Sven Ante Lundberg | Director | 29,432 |
| David Charles Lubner | Director | – |
| Joshua Resnick | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Jean-Paul Kress President, Chief Executive Officer and Chairman | $344.62K | $400.00K | – | $64.01M | $251.43K | $18.06K | $65.03M | – |
| Robert Ang Former President and Chief Executive Officer | $515.03K | – | $184.25K | $1.18M | – | $1.49M | $3.36M | +52% |
| Sandesh Mahatme Chief Financial Officer | $217.85K | $274.00K | $35.26M | $3.54M | $103.00K | $8.97K | $39.41M | – |
| Qing Zuraw Former Chief Development Officer | $243.39K | $100.00K | $2.23M | $8.57M | – | $692.71K | $11.84M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 8, 2021
- Offer price
- $18.00
- Securities offered
- 9,828,017
- Gross proceeds
- $176.90M
- Exchange
- Nasdaq
- First trading day
- Feb 5, 2021
- First-day close
- $37.50+108.3%
- Lock-up ends (est.)
- Aug 4, 2021
“The initial public offering price per share is $18.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 3, 2026, we had 76 full-time employees, 19 of whom held an M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 25, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 30, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 8, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 1, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?